Table 1. Patient Demographics.
| Median (range) / N (%) | |
|---|---|
| N | 87 |
| Age (years) | 55(20-69) |
| Fludarabine dose (mg/m2) | 40(30-40) |
| Weight (kg) | 82.6(41.5-139.5) |
| Male | 56 (64%) |
| Female | 31(36%) |
| Serum creatinine (mg/dL) 1 | 0.9(0.4-1.5) |
| Creatinine clearance (mL/min) 1 | 82.1(49.5-153.2) |
| Recipient CMV positive | 53(61%) |
| Comorbidity Score 2 | |
| 0 | 9 (10%) |
| 1-2 | 32 (37%) |
| ≥3 | 46 (53%) |
| Disease | |
| Acute lymphoblastic leukemia | 6(7%) |
| Acute myelogenous leukemia | 26(30%) |
| Chronic myeloid leukemia | 1(1%) |
| Other leukemia | 6(7%) |
| Myelodysplastic syndrome | 14(16%) |
| Non-Hodgkin's lymphoma | 17(20%) |
| Hodgkin's lymphoma | 8(9%) |
| Other | 9(10%) |
| Graft Source | |
| Bone marrow | 2(2%) |
| Peripheral blood stem cell | 21(24% |
| Cord Blood | 64(74%) |
| 1 umbilical cord | 3(5%) |
| 2 umbilical cords | 61(95%) |
| Donor | |
| HLA Matched-related | 22(25%) |
| Unrelated | 65(75%) |
| Disease Risk3 | |
| Standard risk | 28(32%) |
| High risk | 59(68%) |
| ATG in the conditioning regimen | 40(46%) |
1
obtained on day of pharmacokinetic sampling,
2
Sorror et al (ref 25),
3
Standard risk is defined as acute leukemia in first or second remission and CML in chronic phase, all other malignancies were classified as high risk.